{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T16:45:04Z","timestamp":1791996304213,"version":"4.4.0"},"reference-count":120,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2022,2,8]],"date-time":"2022-02-08T00:00:00Z","timestamp":1644278400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biomolecules"],"abstract":"<jats:p>Cardiovascular diseases are the leading cause of death in people with diabetes. Diabetic cardiomyopathy (DC) is an important complication of diabetes and represents a distinct subtype of heart failure that occurs in absence of cardiovascular diseases. Chronic hyperglycemia and hyperinsulinemia along with insulin resistance and inflammatory milieu are the main mechanisms involved in the pathophysiology of DC. Changes in lifestyle favoring healthy dietary patterns and physical activity, combined with more innovative anti-diabetes therapies, are the current treatment strategies to safeguard the cardiovascular system. This review aims at providing an updated comprehensive overview of clinical, pathogenetic, and molecular aspects of DC, with a focus on the effects of anti-hyperglycemic drugs on the prevention of pump dysfunction and consequently on cardiovascular health in type 2 diabetes.<\/jats:p>","DOI":"10.3390\/biom12020272","type":"journal-article","created":{"date-parts":[[2022,2,9]],"date-time":"2022-02-09T01:03:40Z","timestamp":1644368620000},"page":"272","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Glycemic Control and the Heart: The Tale of Diabetic Cardiomyopathy Continues"],"prefix":"10.3390","volume":"12","author":[{"given":"Miriam","family":"Longo","sequence":"first","affiliation":[{"name":"Department of Advanced Medical and Surgical Sciences, University of Campania \u201cLuigi Vanvitelli\u201d, 80138 Naples, Italy"},{"name":"Division of Endocrinology and Metabolic Diseases, University of Campania \u201cLuigi Vanvitelli\u201d, 80138 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Scappaticcio","sequence":"additional","affiliation":[{"name":"Department of Advanced Medical and Surgical Sciences, University of Campania \u201cLuigi Vanvitelli\u201d, 80138 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Cirillo","sequence":"additional","affiliation":[{"name":"Department of Advanced Medical and Surgical Sciences, University of Campania \u201cLuigi Vanvitelli\u201d, 80138 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonietta","family":"Maio","sequence":"additional","affiliation":[{"name":"Department of Advanced Medical and Surgical Sciences, University of Campania \u201cLuigi Vanvitelli\u201d, 80138 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffaela","family":"Carotenuto","sequence":"additional","affiliation":[{"name":"Department of Advanced Medical and Surgical Sciences, University of Campania \u201cLuigi Vanvitelli\u201d, 80138 Naples, Italy"},{"name":"Division of Endocrinology and Metabolic Diseases, University of Campania \u201cLuigi Vanvitelli\u201d, 80138 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4659-7546","authenticated-orcid":false,"given":"Maria Ida","family":"Maiorino","sequence":"additional","affiliation":[{"name":"Department of Advanced Medical and Surgical Sciences, University of Campania \u201cLuigi Vanvitelli\u201d, 80138 Naples, Italy"},{"name":"Division of Endocrinology and Metabolic Diseases, University of Campania \u201cLuigi Vanvitelli\u201d, 80138 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4748-321X","authenticated-orcid":false,"given":"Giuseppe","family":"Bellastella","sequence":"additional","affiliation":[{"name":"Department of Advanced Medical and Surgical Sciences, University of Campania \u201cLuigi Vanvitelli\u201d, 80138 Naples, Italy"},{"name":"Division of Endocrinology and Metabolic Diseases, University of Campania \u201cLuigi Vanvitelli\u201d, 80138 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Esposito","sequence":"additional","affiliation":[{"name":"Department of Advanced Medical and Surgical Sciences, University of Campania \u201cLuigi Vanvitelli\u201d, 80138 Naples, Italy"},{"name":"Division of Endocrinology and Metabolic Diseases, University of Campania \u201cLuigi Vanvitelli\u201d, 80138 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,2,8]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"American Diabetes Association (2021). 10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes-2021. Diabetes Care, 44, S125\u2013S150.","DOI":"10.2337\/dc21-S010"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1111\/dom.14047","article-title":"Relationship between improvement of glycaemic control and reduction of major cardiovascular events in 15 cardiovascular outcome trials: A meta-analysis with meta-regression","volume":"22","author":"Giugliano","year":"2020","journal-title":"Diabetes Obes. Metab."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1002\/ejhf.1170","article-title":"Type 2 diabetes mellitus and heart failure: A position statement from the Heart Failure Association of the European Society of Cardiology","volume":"20","author":"Petrie","year":"2018","journal-title":"Eur. J. Heart Fail."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1136\/heartjnl-2016-310342","article-title":"Diabetic cardiomyo-pathy","volume":"105","author":"Lee","year":"2019","journal-title":"Heart"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"H\u00f6lscher, M.E., Bode, C., and Bugger, H. (2016). Diabetic Cardiomyopathy: Does the Type of Diabetes Matter?. Int. J. Mol. Sci., 17.","DOI":"10.3390\/ijms17122136"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1007\/s00592-013-0455-0","article-title":"Myocardial dysfunction and chronic heart failure in patients with long-lasting type 1 diabetes: A 7-year prospective cohort study","volume":"50","author":"Konduracka","year":"2013","journal-title":"Acta Diabetol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.pcad.2019.03.003","article-title":"Diabetic cardiomyopathy\u2014A comprehensive updated review","volume":"62","author":"Murtaza","year":"2019","journal-title":"Prog. Cardiovasc. Dis."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1210\/er.2003-0012","article-title":"Diabetic cardiomyopathy: Evidence, mechanisms, and therapeutic implications","volume":"25","author":"Fang","year":"2004","journal-title":"Endocr. Rev."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1007\/s00059-011-3429-4","article-title":"Diabetic cardiomyopathy\u2013Fact or fiction?","volume":"36","author":"Maisch","year":"2011","journal-title":"Herz"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1093\/eurheartj\/ehv134","article-title":"Clinical diabetic cardiomyopathy: A two-faced disease with restrictive and dilated pheno-types","volume":"36","author":"Paulus","year":"2015","journal-title":"Eur. Heart J."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1111\/j.1464-5491.2005.01685.x","article-title":"Early detection of diabetic cardiomyopathy: Usefulness of tissue Doppler imaging","volume":"22","author":"Moio","year":"2005","journal-title":"Diabet. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1161\/CIRCULATIONAHA.107.727826","article-title":"Incidence and prognostic im-plication of unrecognized myocardial scar characterized by cardiac magnetic resonance in diabetic patients without clinical evidence of myocardial infarction","volume":"118","author":"Kwong","year":"2008","journal-title":"Circulation"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1016\/j.jcmg.2020.10.009","article-title":"Diabetic Cardiomiopathy Progression is Triggered by miR122-5p and Involves Extracellular Matrix: A 5-Year Prospective Study","volume":"14","author":"Pofi","year":"2021","journal-title":"JACC Cardiovasc. Imaging"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1067\/mhj.2001.113215","article-title":"Utility of B-natriuretic peptide as a rapid, point-of-care test for screening patients undergoing echocardiography to determine left ventricular dysfunction","volume":"141","author":"Maisel","year":"2001","journal-title":"Am. Heart J."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"e005539","DOI":"10.1161\/JAHA.117.005539","article-title":"Diabetes Mellitus, Microalbuminuria, and Subclinical Cardiac Disease: Identification and Monitoring of Individ-uals at Risk of Heart Failure","volume":"6","author":"Swoboda","year":"2017","journal-title":"J. Am. Heart Assoc."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1161\/CIRCRESAHA.120.315913","article-title":"Basic Mechanisms of Diabetic Heart Disease","volume":"126","author":"Ritchie","year":"2020","journal-title":"Circ. Res."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1161\/CIRCRESAHA.117.311586","article-title":"Diabetic Cardiomyopathy: An Update of Mechanisms Contributing to This Clinical Entity","volume":"122","author":"Jia","year":"2018","journal-title":"Circ. Res."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/s10741-011-9257-z","article-title":"Diabetic cardiomyopathy: Understanding the molecular and cellular basis to progress in diagnosis and treatment","volume":"17","year":"2012","journal-title":"Heart Fail. Rev."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/j.yjmcc.2011.01.007","article-title":"Metabolism, hypoxia and the diabetic heart","volume":"50","author":"Heather","year":"2011","journal-title":"J. Mol. Cell Cardiol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1161\/01.CIR.0000139340.88769.D5","article-title":"Cardiac metabolism as a target for the treatment of heart failure","volume":"110","author":"Taegtmeyer","year":"2004","journal-title":"Circulation"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"270","DOI":"10.4093\/dmj.2018.0101","article-title":"Role of the Pyruvate Dehydrogenase Complex in Metabolic Remodeling: Differential Pyruvate Dehydrogenase Complex Functions in Metabolism","volume":"42","author":"Park","year":"2018","journal-title":"Diabetes Metab. J."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1186\/s12933-020-01177-3","article-title":"Insulin directly stimulates mitochondrial glucose oxidation in the heart","volume":"19","author":"Karwi","year":"2020","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1161\/CIRCULATIONAHA.119.044452","article-title":"The Role of Nonglycolytic Glucose Metabolism in Myocardial Recovery Upon Mechanical Unloading and Circulatory Support in Chronic Heart Failure","volume":"142","author":"Badolia","year":"2020","journal-title":"Circulation"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.jacbts.2016.06.009","article-title":"Evidence of Glycolysis Up-Regulation and Pyruvate Mitochondrial Oxidation Mismatch During Mechanical Unloading of the Failing Human Heart: Implications for Cardiac eloading and Conditioning","volume":"1","author":"Diakos","year":"2016","journal-title":"JACC Basic Transl. Sci."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1161\/01.CIR.0000012467.61045.87","article-title":"Adaptation and maladaptation of the heart in diabetes: Part II: Potential mechanisms","volume":"105","author":"Young","year":"2002","journal-title":"Circulation"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"H1137","DOI":"10.1152\/ajpheart.2001.281.3.H1137","article-title":"Altered SR protein expression associated with contractile dysfunction in diabetic rat hearts","volume":"281","author":"Zhong","year":"2001","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"R1787","DOI":"10.1152\/ajpregu.00059.2007","article-title":"Mechanisms of impaired calcium handling underlying subclinical diastolic dysfunction in diabetes","volume":"293","author":"Lacombe","year":"2007","journal-title":"Am. J. Physiol. Regul. Integr. Comp. Physiol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1515\/JPEM.2003.16.1.5","article-title":"Glucotoxicity and beta-cell failure in type 2 diabetes mellitus","volume":"16","author":"Kaiser","year":"2003","journal-title":"J. Pediatr. Endocrinol. Metab."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"353","DOI":"10.4093\/dmj.2015.39.5.353","article-title":"Interaction between Glucose and Lipid Metabolism: More than Diabetic Dyslipidemia","volume":"39","author":"Parhofer","year":"2015","journal-title":"Diabetes Metab. J."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s12933-019-0865-6","article-title":"Cardiovascular organ damage in type 2 diabetes mellitus: The role of lipids and inflammation","volume":"18","author":"Kozakova","year":"2019","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1093\/eurheartj\/ehy903","article-title":"Obesity-induced activation of JunD promotes myocardial lipid accumulation and metabolic cardiomyopathy","volume":"40","author":"Costantino","year":"2019","journal-title":"Eur. Heart J."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s12933-020-01188-0","article-title":"Impact of peroxisome proliferator-activated receptor-\u03b1 on diabetic cardiomyopathy","volume":"20","author":"Wang","year":"2021","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/nrendo.2015.216","article-title":"Insulin resistance and hyperinsulinaemia in diabetic cardiomyopathy","volume":"12","author":"Jia","year":"2016","journal-title":"Nat. Rev. Endocrinol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s12929-016-0309-5","article-title":"PPARs modulate cardiac metabolism and mitochondrial function in diabetes","volume":"24","author":"Lee","year":"2017","journal-title":"J. Biomed. Sci."},{"key":"ref_35","first-page":"3118","article-title":"Insulin resistance improves metabolic and contractile efficiency in stressed rat heart","volume":"26","author":"Harmancey","year":"2012","journal-title":"FASEB J. Off. Publ. Fed. Am. Soc. Exp. Biol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1016\/j.metabol.2012.02.013","article-title":"Over-nutrition and metabolic cardiomyopathy","volume":"61","author":"Mandavia","year":"2012","journal-title":"Metabolism"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.bbrc.2007.01.141","article-title":"AMPK-mediated increase in myocardial long-chain fatty acid uptake critically depends on sarcolemmal CD36","volume":"355","author":"Habets","year":"2007","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1161\/01.RES.0000264104.25265.b6","article-title":"CD36 deficiency rescues lipotoxic cardiomyopathy","volume":"100","author":"Yang","year":"2007","journal-title":"Circ. Res."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/S0022-2275(20)31637-0","article-title":"Defect in human myocardial long-chain fatty acid uptake is caused by FAT\/CD36 mutations","volume":"42","author":"Tanaka","year":"2001","journal-title":"J. Lipid Res."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.pharmthera.2016.11.013","article-title":"Cardiac oxidative stress in diabetes: Mechanisms and therapeutic potential","volume":"172","author":"Faria","year":"2017","journal-title":"Pharmacol. Ther."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1136\/heartjnl-2017-311448","article-title":"Reactive oxygen species signalling in the diabetic heart: Emerging prospect for therapeutic targeting","volume":"104","author":"Wilson","year":"2018","journal-title":"Heart"},{"key":"ref_42","first-page":"788","article-title":"Smad3 Signaling Promotes Fibrosis While Preserving Cardiac and Aortic Geometry in Obese Diabetic Mice","volume":"8","author":"Biernacka","year":"2015","journal-title":"Circulation"},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Maruhashi, T., and Higashi, Y. (2021). Pathophysiological Association between Diabetes Mellitus and Endothelial Dysfunction. Antioxidants, 10.","DOI":"10.3390\/antiox10081306"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1161\/CIRCRESAHA.110.217117","article-title":"Activation of protein kinase C isoforms and its impact on diabetic complications","volume":"106","author":"Geraldes","year":"2010","journal-title":"Circ. Res."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.cmet.2012.11.012","article-title":"Vascular complications of diabetes: Mechanisms of injury and protective factors","volume":"17","author":"King","year":"2013","journal-title":"Cell Metab."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.redox.2018.09.025","article-title":"New Insights into Oxidative Stress and Inflammation during Diabetes Mellitus-Accelerated Atherosclerosis","volume":"20","author":"Yuan","year":"2019","journal-title":"Redox Biol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"716332","DOI":"10.3389\/fphar.2021.716332","article-title":"Potential Role of Protein Kinase C in the Pathophysiology of Diabetes-Associated Atherosclerosis","volume":"12","author":"Lien","year":"2021","journal-title":"Front. Pharmacol."},{"key":"ref_48","first-page":"847827","article-title":"Activation of Toll-like repceptors and inflammasome complexes in the diabetic cardiomyopathy-associated inflammation","volume":"2014","author":"Ioan","year":"2014","journal-title":"Int. J. Endocrinol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"3661","DOI":"10.1210\/en.2017-00294","article-title":"Aldose reductase mediates NLRP3 inflammasome-initiated innate immune response in hyperglycemia-induced Thp1 monocytes and male mice","volume":"158","author":"Pal","year":"2017","journal-title":"Endocrinology"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1161\/CIRCRESAHA.110.223545","article-title":"Oxidative stress and diabetic complications","volume":"107","author":"Giacco","year":"2010","journal-title":"Circ. Res."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s10741-013-9374-y","article-title":"Advanced glycation end products: Role in pathology of diabetic cardiomyopathy","volume":"19","author":"Bodiga","year":"2014","journal-title":"Heart Fail. Rev."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1111\/j.1582-4934.2008.00547.x","article-title":"Advanced glycation endproduct (AGE) accumulation and AGE receptor (RAGE) up-regulation contribute to the onset of diabetic cardiomyopathy","volume":"13","author":"Ma","year":"2009","journal-title":"J. Cell Mol. Med."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"7489795","DOI":"10.1155\/2020\/7489795","article-title":"Association of Glycemic Indices (Hyperglycemia, Glucose Variability, and Hypoglycemia) with Oxidative Stress and Diabetic Complications","volume":"2020","author":"Papachristoforou","year":"2020","journal-title":"J. Diabetes Res."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"205","DOI":"10.3389\/fendo.2014.00205","article-title":"Autonomic neuropathy in diabetes mellitus","volume":"5","author":"Verrotti","year":"2014","journal-title":"Front. Endocrinol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"8917578","DOI":"10.1155\/2016\/8917578","article-title":"Update on RAAS Modulation for the Treatment of Diabetic Cardiovascular Disease","volume":"2016","author":"Bernardi","year":"2016","journal-title":"J. Diabetes Res."},{"key":"ref_56","first-page":"e29","article-title":"American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics: 2015 update: A report from the American Heart Association","volume":"131","author":"Mozaffarian","year":"2015","journal-title":"Circulation"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"2668","DOI":"10.1161\/01.CIR.103.22.2668","article-title":"Glycemic control and heart failure among adult patients with diabetes","volume":"103","author":"Iribarren","year":"2001","journal-title":"Circulation"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"108952","DOI":"10.1016\/j.diabres.2021.108952","article-title":"Evaluation of the effects of glycated hemoglobin on cardiac function in patients with short-duration type 2 diabetes mellitus: A cardiovascular magnetic resonance study","volume":"178","author":"Zhou","year":"2021","journal-title":"Diabetes Res. Clin. Pract."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s00592-020-01605-6","article-title":"Predictions of diabetes complications and mortality using hba1c variability: A 10-year observational cohort study","volume":"58","author":"Lee","year":"2021","journal-title":"Acta Diabetol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/1475-2840-10-47","article-title":"Cardiac lipid content is unresponsive to a physical activity training intervention in type 2 diabetic patients, despite improved ejection fraction","volume":"10","author":"Meex","year":"2011","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.coph.2021.06.005","article-title":"Mediterranean diet in type 2 diabetes: An updated overview of pharmacological activities of cardiometabolic and reproductive outcomes","volume":"60","author":"Longo","year":"2021","journal-title":"Curr. Opin. Pharmacol."},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Maiuolo, J., Carresi, C., Gliozzi, M., Musolino, V., Scarano, F., Coppoletta, A.R., Guarnieri, L., Nucera, S., Scicchitano, M., and Bosco, F. (2021). Effects of Bergamot Polyphenols on Mitochondrial Dysfunction and Sarcoplasmic Reticulum Stress in Diabetic Cardiomyopathy. Nutrients, 13.","DOI":"10.3390\/nu13072476"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.numecd.2020.08.003","article-title":"The association of the Mediterranean diet with heart failure risk in a Dutch population","volume":"31","author":"Strengers","year":"2021","journal-title":"Nutr. Metab. Cardiovasc. Dis."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1136\/bmj.39314.620174.80","article-title":"Benefits and harms of antidiabetic agents in patients with diabetes and heart failure: Systematic review","volume":"335","author":"Eurich","year":"2007","journal-title":"BMJ"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1111\/j.1440-1681.2010.05470.x","article-title":"Metformin improves cardiac function in rats via activation of AMP-activated protein kinase","volume":"38","author":"Wang","year":"2011","journal-title":"Clin. Exp. Pharm. Physiol."},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Yang, Z., Wang, M., Zhang, Y., Cai, F., Jiang, B., Zha, W., and Yu, W. (2020). Metformin Ameliorates Diabetic Cardiomyopathy by Activating the PK2\/PKR Pathway. Front. Physiol., 11.","DOI":"10.3389\/fphys.2020.00425"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1530\/EJE-10-0624","article-title":"Metformin is associated with improved left ventricular diastolic function measured by tissue Doppler imaging in patients with diabetes","volume":"163","author":"Andersson","year":"2010","journal-title":"Eur. J. Endocrinol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1007\/s12020-021-02687-0","article-title":"Metformin in non-diabetic patients with metabolic syndrome and diastolic dysfunction: The MET-DIME randomized trial","volume":"72","author":"Sampaio","year":"2021","journal-title":"Endocrine"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1007\/s00125-017-4337-9","article-title":"Impact of metformin on cardiovascular disease: A meta-analysis of randomised trials among people with type 2 diabetes","volume":"60","author":"Griffin","year":"2017","journal-title":"Diabetologia"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.ejps.2009.09.004","article-title":"Triple verses glimepiride plus metformin therapy on cardiovascular risk biomarkers and diabetic cardiomyopathy in insulin resistance type 2 diabetes mellitus rats","volume":"38","author":"Sharma","year":"2009","journal-title":"Eur. J. Pharm. Sci."},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"American Diabetes Association (2021). 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes\u20142021. Diabetes Care, 44, S111\u2013S124.","DOI":"10.2337\/dc21-S009"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"e005379","DOI":"10.1161\/JAHA.116.005379","article-title":"Comparative Safety of Sulfonylurea and Metformin Monotherapy on the Risk of Heart Failure: A Cohort Study","volume":"6","author":"Roumie","year":"2017","journal-title":"J. Am. Heart Assoc."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/S2213-8587(19)30422-X","article-title":"Association of glucose-lowering medications with cardiovascular outcomes: An umbrella review and evidence map","volume":"8","author":"Zhu","year":"2020","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1161\/CIRCULATIONAHA.105.549618","article-title":"Peroxisome proliferator-activated receptor-gamma activation with pioglitazone improves endothelium-dependent dilation in nondiabetic patients with major cardiovascular risk factors","volume":"113","author":"Campia","year":"2006","journal-title":"Circulation"},{"key":"ref_75","first-page":"812","article-title":"Effects of PPAR\u03b3 agonist pioglitazone on cardiac fibrosis in diabetic mice by regulating PTEN\/AKT\/FAK pathway","volume":"25","author":"Zhang","year":"2021","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/s00210-020-01979-y","article-title":"Cardioprotective effect of pioglitazone and curcumin against diabetic cardiomyopathy in type 1 diabetes mellitus: Impact on CaMKII\/NF-\u03baB\/TGF-\u03b21 and PPAR-\u03b3 signaling pathway","volume":"394","author":"Gbr","year":"2021","journal-title":"Naunyn-Schmiedeberg\u2019s Arch. Pharmacol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1016\/S0140-6736(05)67528-9","article-title":"PROactive Investigators. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): A randomised controlled trial","volume":"366","author":"Dormandy","year":"2005","journal-title":"Lancet"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1016\/S0140-6736(09)60953-3","article-title":"Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): A multicentre, randomised, open-label trial","volume":"373","author":"Home","year":"2009","journal-title":"Lancet"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s12933-021-01213-w","article-title":"Sodium-glucose transporter-2 inhibitors for prevention and treatment of cardiorenal complications of type 2 diabetes","volume":"20","author":"Giugliano","year":"2021","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1111\/dom.14374","article-title":"Sodium-glucose co-transporter-2 inhibitors for the prevention of cardiorenal outcomes in type 2 diabetes: An updated meta-analysis","volume":"23","author":"Giugliano","year":"2021","journal-title":"Diabetes Obes. Metab."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s13300-010-0006-4","article-title":"Quantitative PCR tissue expression profiling of the human SGLT2 gene and related family members","volume":"1","author":"Chen","year":"2010","journal-title":"Diabetes Ther."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1001\/jamacardio.2017.2275","article-title":"Effects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure: Proposal of a Novel Mechanism of Action","volume":"2","author":"Packer","year":"2017","journal-title":"JAMA Cardiol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s12933-019-0980-4","article-title":"Sodium-glucose cotransporter 2 inhibitor Dapagliflozin attenuates diabetic cardiomyopathy","volume":"19","author":"Arow","year":"2020","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s10557-020-06978-y","article-title":"Dapagliflozin and Ticagrelor Have Additive Effects on the Attenuation of the Activation of the NLRP3 Inflammasome and the Progression of Diabetic Cardiomyopathy: An AMPK-mTOR Interplay","volume":"34","author":"Chen","year":"2020","journal-title":"Cardiovasc. Drugs Ther."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s12933-019-0816-2","article-title":"SGLT2 inhibition with empagliflozin attenuates myocardial oxidative stress and fibrosis in diabetic mice heart","volume":"18","author":"Li","year":"2019","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"165807","DOI":"10.1016\/j.bbadis.2020.165807","article-title":"Empagliflozin improves left ventricular diastolic function of db\/db mice","volume":"1866","author":"Moellmann","year":"2020","journal-title":"Biochim. Biophys. Acta (BBA) Mol. Basis Dis."},{"key":"ref_87","doi-asserted-by":"crossref","unstructured":"Oka, S., Kai, T., Hoshino, K., Watanabe, K., Nakamura, J., Abe, M., and Watanabe, A. (2021). Effects of empagliflozin in different phases of diabetes mellitus-related cardiomyopathy: A prospective observational study. BMC Cardiovasc. Disord., 21.","DOI":"10.1186\/s12872-021-02024-3"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s12933-021-01229-2","article-title":"The residual cardiorenal risk in type 2 diabetes","volume":"20","author":"Giugliano","year":"2021","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/j.cmet.2013.04.008","article-title":"Pharmacology, physiology, and mechanisms of incretin hormone action","volume":"17","author":"Campbell","year":"2013","journal-title":"Cell Metab."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.cmet.2016.06.009","article-title":"The Cardiovascular Biology of Glucagon-like Peptide-1","volume":"24","author":"Drucker","year":"2016","journal-title":"Cell Metab."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1210\/en.2018-00004","article-title":"GLP-1 Receptor Expression Within the Human Heart","volume":"159","author":"Baggio","year":"2018","journal-title":"Endocrinology"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"202","DOI":"10.3389\/fendo.2019.00202","article-title":"Exenatide Protects Against Cardiac Dysfunction by Attenuating Oxidative Stress in the Diabetic Mouse Heart","volume":"10","author":"Ding","year":"2019","journal-title":"Front. Endocrinol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.cjca.2020.02.098","article-title":"The GLP-1 Receptor Agonist Liraglutide Increases Myocardial Glucose Oxidation Rates via Indirect Mechanisms and Mitigates Experimental Diabetic Cardiomyopathy","volume":"37","author":"Almutairi","year":"2021","journal-title":"Can. J. Cardiol."},{"key":"ref_94","doi-asserted-by":"crossref","unstructured":"Trang, N.N., Chung, C.C., Lee, T.W., Cheng, W.L., Kao, Y.H., Huang, S.Y., Lee, T.I., and Chen, Y.J. (2021). Empagliflozin and Liraglutide Differentially Modulate Cardiac Metabolism in Diabetic Cardiomyopathy in Rats. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22031177"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/j.cardfail.2006.08.211","article-title":"Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure","volume":"12","author":"Sokos","year":"2006","journal-title":"J. Card. Fail"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1001\/jama.2016.10260","article-title":"NHLBI, Heart Failure Clinical Research Network. Effects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial","volume":"316","author":"Margulies","year":"2016","journal-title":"JAMA"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s12933-019-0857-6","article-title":"Effect of liraglutide on cardiac function in patients with type 2 diabetes mellitus: Randomized placebo-controlled trial","volume":"18","author":"Bizino","year":"2019","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1002\/ejhf.657","article-title":"Effect of liraglutide, a glucagon-like peptide-1 analogue, on left ventricular function in stable chronic heart failure patients with and without diabetes (LIVE)-a multicentre, double-blind, randomised, placebo-controlled trial","volume":"19","author":"Jorsal","year":"2017","journal-title":"Eur. J. Heart Fail."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1186\/s12933-021-01401-8","article-title":"Improvement of glycemic control and reduction of major cardiovascular events in 18 cardiovascular outcome trials: An updated meta-regression","volume":"20","author":"Maiorino","year":"2021","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1161\/CIRCHEARTFAILURE.112.000057","article-title":"Circulating dipeptidyl peptidase IV activity correlates with cardiac dysfunction in human and experimental heart failure","volume":"6","author":"Salles","year":"2013","journal-title":"Circ. Heart Fail"},{"key":"ref_101","doi-asserted-by":"crossref","unstructured":"Suda, M., Shimizu, I., Yoshida, Y., Hayashi, Y., Ikegami, R., Katsuumi, G., Wakasugi, T., Yoshida, Y., Okuda, S., and Soga, T. (2017). Inhibition of dipeptidyl peptidase-4 ameliorates cardiac ischemia and systolic dysfunction by up-regulating the FGF-2\/EGR-1 pathway. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0182422"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.2147\/DDDT.S109287","article-title":"Sitagliptin attenuates cardiomyopathy by modulating the JAK\/STAT signaling pathway in experimental diabetic rats","volume":"10","author":"Hasan","year":"2016","journal-title":"Drug Des. Devel. Ther."},{"key":"ref_103","first-page":"841","article-title":"Sitagliptin inhibits EndMT in vitro and improves cardiac function of diabetic rats through the SDF-1\u03b1\/PKA pathway","volume":"23","author":"Wu","year":"2019","journal-title":"Eur Rev. Med. Pharmacol. Sci."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1186\/1758-5996-6-103","article-title":"Left ventricular diastolic function in patients with type 2 diabetes treated with a dipeptidyl peptidase-4 inhibitor-A pilot study","volume":"6","author":"Nogueira","year":"2014","journal-title":"Diabetol. Metab. Syndr."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/s12933-017-0546-2","article-title":"PROLOGUE Study Investigators. Effect of sitagliptin on the echocardiographic parameters of left ventricular diastolic function in patients with type 2 diabetes: A subgroup analysis of the PROLOGUE study","volume":"16","author":"Yamada","year":"2017","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/s12933-015-0242-z","article-title":"Comparison of effects of sitagliptin and voglibose on left ventricular diastolic dysfunction in patients with type 2 diabetes: Results of the 3D trial","volume":"14","author":"Oe","year":"2015","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1056\/NEJMoa1307684","article-title":"SAVOR-TIMI 53 Steering Committee and Investigators. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus","volume":"369","author":"Scirica","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1016\/S0140-6736(14)62225-X","article-title":"EXAMINE Investigators. Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: A multicentre, randomised, double-blind trial","volume":"385","author":"Zannad","year":"2015","journal-title":"Lancet"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1001\/jama.2019.13772","article-title":"CAROLINA Investigators. Effect of Linagliptin vs Glimepiride on Major Adverse Cardiovascular Outcomes in Patients With Type 2 Diabetes: The CAROLINA Randomized Clinical Trial","volume":"322","author":"Rosenstock","year":"2019","journal-title":"JAMA"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1056\/NEJMoa1501352","article-title":"TECOS Study Group. Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes","volume":"373","author":"Green","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_111","first-page":"8","article-title":"IL-1\u03b2 and Statin Treatment in Patients with Myocardial Infarction and Diabetic Cardiomyopathy","volume":"23","author":"Liberale","year":"2019","journal-title":"J. Clin. Med."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s10557-013-6498-1","article-title":"Rosuvastatin alleviates diabetic cardiomyopathy by inhibiting NLRP3 inflammasome and MAPK pathways in a type 2 diabetes rat model","volume":"28","author":"Luo","year":"2014","journal-title":"Cardiovasc. Drugs. Ther."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"1092015","DOI":"10.1155\/2017\/1092015","article-title":"Simvastatin Ameliorates Diabetic Cardiomyopathy by Attenuating Oxidative Stress and Inflammation in Rats","volume":"2017","author":"Hasan","year":"2017","journal-title":"Oxid. Med. Cell Longev."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"1067853","DOI":"10.1155\/2018\/1067853","article-title":"Effects of Pravastatin on Type 1 Diabetic Rat Heart with or without Blood Glycemic Control","volume":"2018","author":"Min","year":"2018","journal-title":"J. Diabetes Res."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/s10735-015-9625-4","article-title":"Atorvastatin alleviates experimental diabetic cardiomyopathy by suppressing apoptosis and oxidative stress","volume":"46","author":"Firgany","year":"2015","journal-title":"J. Mol. Histol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"e0180103","DOI":"10.1371\/journal.pone.0180103","article-title":"Atorvastatin reduces \u03b2-Adrenergic dysfunction in rats with diabetic cardiomyopathy","volume":"12","author":"Carillion","year":"2017","journal-title":"PLoS ONE"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"634900","DOI":"10.3389\/fcell.2021.634900","article-title":"Combined Administration of Metformin and Atorvastatin Attenuates Diabetic Cardiomyopathy by Inhibiting Inflammation, Apoptosis, and Oxidative Stress in Type 2 Diabetic Mice","volume":"16","author":"Jia","year":"2021","journal-title":"Front Cell Dev. Biol."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1042\/CS20150623","article-title":"Fenofibrate increases cardiac autophagy via FGF21\/SIRT1 and prevents fibrosis and inflammation in the hearts of Type 1 diabetic mice","volume":"130","author":"Zhang","year":"2016","journal-title":"Clin. Sci."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"e020395","DOI":"10.1161\/JAHA.120.020395","article-title":"Compliance in Primary Prevention With Statins and Associations With Cardiovascular Risk and Death in a Low-Risk Population With Type 2 Diabetes Mellitus","volume":"6","author":"Malmborg","year":"2021","journal-title":"J. Am. Heart Assoc."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1093\/eurheartj\/ehz486","article-title":"ESC Scientific Document Group. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD","volume":"41","author":"Cosentino","year":"2020","journal-title":"Eur. Heart J."}],"container-title":["Biomolecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2218-273X\/12\/2\/272\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T22:16:25Z","timestamp":1760134585000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2218-273X\/12\/2\/272"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,8]]},"references-count":120,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2022,2]]}},"alternative-id":["biom12020272"],"URL":"https:\/\/doi.org\/10.3390\/biom12020272","relation":{},"ISSN":["2218-273X"],"issn-type":[{"value":"2218-273X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,8]]}}}